10-Q: Mirion Technologies Q2 2026 Earnings: Revenue Up, Net Income Down

Mirion Technologies reported a significant increase in Q2 2026 revenue driven by its Nuclear & Safety segment, though net income saw a slight decrease due to foreign currency fluctuations and increased operating expenses.

Summary

• Mirion Technologies reported total revenues of $266.8 million for the three months ended June 30, 2026, an increase of 20.1% compared to $222.9 million in the same period last year.
• For the six months ended June 30, 2026, revenues were $524.4 million, up 23.4% from $424.9 million in the prior year period.
• Net income attributable to Mirion Technologies, Inc. was $7.7 million for the three months ended June 30, 2026, a decrease from $8.3 million in the prior year period.
• For the six months ended June 30, 2026, net income was $4.3 million, down from $8.9 million in the prior year period.
• The Nuclear & Safety segment saw revenue growth of 31.4% for the quarter and 35.1% for the six months, driven by acquisitions, price increases, and organic volume growth.
• The Medical segment experienced a slight revenue decrease of 0.7% for the quarter but an increase of 2.0% for the six months, impacted by volume declines in Asia-Pacific and dosimetry sales, partially offset by price increases.
• Selling, general, and administrative (SG&A) expenses increased by $22.5 million for the quarter and $49.6 million for the six months, largely due to increased employee compensation, amortization from acquisitions, and new AI function costs.
• Backlog remained strong at $1,138.6 million as of June 30, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as moderately positive, with strong revenue growth and a robust backlog, though tempered by a decrease in net income due to currency impacts and increased operating expenses.

Positives

• Total revenues increased by 20.1% to $266.8 million for the three months ended June 30, 2026, and by 23.4% to $524.4 million for the six months ended June 30, 2026.
• The Nuclear & Safety segment showed robust revenue growth of 31.4% for the quarter and 35.1% for the six months, driven by acquisitions, price increases, and organic volume growth.
• Gross profit increased by $30.6 million to $133.1 million for the three months ended June 30, 2026, and by $53.6 million to $252.2 million for the six months ended June 30, 2026.
• Income from operations increased to $17.9 million for the three months ended June 30, 2026, and to $21.6 million for the six months ended June 30, 2026.
• Segment income from operations for Nuclear & Safety increased by $7.0 million for the quarter and $6.2 million for the six months.
• Segment income from operations for Medical increased by $3.9 million for the quarter and $5.0 million for the six months.
• Backlog remained strong at $1,138.6 million as of June 30, 2026.
• Net cash provided by operating activities increased by $29.4 million to $77.4 million for the six months ended June 30, 2026.

Negatives

• Net income attributable to Mirion Technologies, Inc. decreased to $7.7 million for the three months ended June 30, 2026, from $8.3 million in the prior year period.
• For the six months ended June 30, 2026, net income decreased to $4.3 million from $8.9 million in the prior year period.
• The Medical segment experienced a revenue decrease of 0.7% for the three months ended June 30, 2026, primarily due to decreased volume in Asia-Pacific and dosimetry product sales.
• Selling, general, and administrative (SG&A) expenses increased significantly by $22.5 million for the quarter and $49.6 million for the six months, driven by higher employee compensation, amortization, and new AI function costs.
• A $1.0 million unrealized foreign currency loss was recorded for the three months ended June 30, 2026, compared to a $13.5 million gain in the prior year period.
• For the six months ended June 30, 2026, a $4.7 million unrealized foreign currency loss was recorded, compared to a $16.3 million gain in the prior year period.
• Corporate and other costs increased by $2.9 million for the quarter and $8.2 million for the six months, primarily due to stock compensation and AI function costs.
• The effective income tax rate increased to 28.3% for the three months and 23.0% for the six months ended June 30, 2026, compared to negative rates in the prior year periods.

Risks

• Geopolitical and trade conditions, including those related to Russia, China, and the Middle East conflict, could continue to impact the company through inflation, supply chain disruptions, and market volatility.
• Inflation and rising interest rates may increase debt service costs and impact operational challenges.
• Sanctions imposed by governments against Russia, China, and related parties could increase costs and affect operations.
• China's expanding localization requirements may necessitate changes in manufacturing or sourcing, potentially increasing costs or delaying sales.
• The use of Artificial Intelligence (AI) and machine learning technologies carries risks of legal liability, regulatory action, and reputational harm due to potential inaccuracies, biases, or security vulnerabilities.
• Fixed-price contracts carry inherent risks of losses from underestimating costs, operational difficulties, or unforeseen changes over the contract period.
• The company's global operations are subject to foreign currency exchange rate fluctuations, interest rate changes, tariffs, and trade disruptions.
• The company faces risks related to government contracts, including budget cycles and potential spending cuts.

Future Outlook

The company's future performance is expected to be influenced by trends in the nuclear and medical end markets, including growth in data centers, AI, SMRs, and increased government and industry acceptance of nuclear energy. Medical segment growth is anticipated from aging demographics, low penetration in emerging markets, and adoption of advanced RT QA solutions. The company also anticipates continued impact from geopolitical and trade conditions, inflation, and interest rates.

Management Comments

• Mirion management believes the Certrec business will be pivotal in expanding offerings in the nuclear power market and further strengthening the development of Mirion's digital ecosystem.
• Mirion management believes that Paragon will provide Mirion's nuclear power customers with a more comprehensive suite of product offerings and services to meet their growing needs.
• Mirion management believes that Paragon significantly enhances Mirion's presence in the U.S. nuclear power market and the developing SMR commercial entrants.

Industry Context

StockSavvy.ai notes that Mirion Technologies operates in critical sectors of nuclear safety and medical technology. The company's performance is closely tied to global energy policies, healthcare trends, and advancements in nuclear technology like Small Modular Reactors (SMRs). The reported revenue growth, particularly in the Nuclear & Safety segment, aligns with increasing global interest in nuclear power as a clean energy source and the ongoing demand for advanced radiation detection and monitoring solutions.

Comparison to Industry Standards

• The company's revenue growth in the Nuclear & Safety segment, driven by acquisitions and organic factors, appears strong compared to general industrial sector growth rates.
• The Medical segment's performance, while showing mixed results, reflects broader healthcare industry trends of increasing demand for quality assurance and advanced treatment solutions.
• The company's focus on SMRs positions it within a nascent but potentially high-growth area of the nuclear energy industry, which is still developing its own industry standards and benchmarks.
• The reported backlog of over $1.1 billion suggests a healthy pipeline of future projects, which is a positive indicator compared to companies with shorter-term revenue visibility.

Legal Proceedings

• The company is subject to various legal proceedings, claims, litigation, investigations, and contingencies arising in the ordinary course of business. The resolution of these matters is not expected to have a material adverse effect on financial condition or results of operations, though litigation can have adverse impacts due to costs and diversion of management resources.

Stakeholder Impact

• Shareholders: Potential for increased revenue and backlog, but offset by decreased net income in the current period and increased operating expenses.
• Employees: Increased compensation costs noted, particularly related to new acquisitions and AI function development.
• Customers: Continued provision of critical products and services in nuclear safety and medical technology sectors.
• Suppliers: Potential impact from geopolitical and trade conditions affecting supply chains.
• Creditors: Company remains in compliance with debt covenants, with a stable debt profile.

Next Steps

• Continue to monitor geopolitical and trade conditions, inflation, and interest rates.
• Manage supply chain challenges and potential difficulties with third-party manufacturers.
• Focus on integrating recent acquisitions (Certrec and Paragon) and realizing expected synergies.
• Continue to develop and implement strategies related to artificial intelligence and machine learning technologies.
• Monitor developments in the China market, including competition and procurement policies.
• Manage risks associated with fixed-price contracts and potential cost overruns.
• Evaluate and respond to evolving government environmental objectives and nuclear energy policies.
• Continue to manage debt obligations and capital structure.

Key Dates

Recommendation

The company demonstrates strong revenue growth and a solid backlog, indicating operational strength. However, the decrease in net income due to currency fluctuations and rising operating expenses, coupled with ongoing geopolitical and economic uncertainties, warrants a cautious approach. A 'hold' recommendation reflects the balance between positive operational trends and potential headwinds.

Keywords

Mirion Technologies, Nuclear & Safety, Medical, Radiation Detection, Nuclear Power, Radiation Therapy, Form 10-Q, Quarterly Report